Research Topics
Genomes and Genes | Jeffrey KordowerSummaryAffiliation: Rush University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Trophic factor gene therapy for Parkinson's diseaseJeffrey H Kordower
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
Mov Disord 28:96-109. 2013..Similar success has been gleaned in open-label clinical trials, although this has yet to be realized in double-blinded analyses. This work reviews the field of trophic factor gene delivery for PD. © 2013 Movement Disorder Society...
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's diseaseJ H Kordower
Department of Neurological Sciences, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
Science 290:767-73. 2000..These data indicate that GDNF delivery using a lentiviral vector system can prevent nigrostriatal degeneration and induce regeneration in primate models of PD and might be a viable therapeutic strategy for PD patients...- Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeysJeffrey H Kordower
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
Ann Neurol 60:264-8. 2006..Furthermore, administration of PSI or epoxomicin to monkeys in an attempt to extend the model to a primate species failed. Currently, systemic proteasome inhibition is not a reliable model for Parkinson's disease... - Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?Jeffrey H Kordower
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Exp Neurol 209:34-40. 2008.... - Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's diseaseJeffrey H Kordower
Department of Neurological Sciences and Center for Brain Repair, Rush University Medical Center, 1735 West Harrison Street, Chicago, Illinois 60612, USA
Nat Med 14:504-6. 2008..These findings have implications for cell-based therapies and for understanding the cause of Parkinson's disease... - Transplanted dopaminergic neurons develop PD pathologic changes: a second case reportJeffrey H Kordower
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 23:2303-6. 2008..Some grafted cell displayed a loss of tyrosine hydroxylase. These data support the emerging concept that PD-like pathology is seen in young grafted neurons when they survive long term... 
Long-term gonadal hormone treatment and endogenous neurogenesis in the dentate gyrus of the adult female monkeyJeffrey H Kordower
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Exp Neurol 224:252-7. 2010..7), OVX-E-Cyc (1783+/-415.6), OVX-E-Con+/-P-Cyc (1721+/-229.6), and OVX-Veh (1263+/-106.3), but a trend towards increased BrdU-ir cells was observed in all the experimental groups...- Transfer of host-derived α synuclein to grafted dopaminergic neurons in ratJeffrey H Kordower
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
Neurobiol Dis 43:552-7. 2011.... - Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairmentJ H Kordower
Research Center for Brain Repair, Department of Neurological Sciences, Chicago, IL, USA
Ann Neurol 49:202-13. 2001.... - In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's diseaseJeffrey H Kordower
Department of Neurological Sciences and Research Center for Brain Repair, Rush Presbyterian St Luke s Medical Center, Chicago IL 60612, USA
Ann Neurol 53:S120-32; discussion S132-4. 2003..Although there are several ways that gene therapy can be applied for PD, this review focuses on in vivo gene delivery of glial cell line-derived neurotrophic factor (GDNF) as a neuroprotective strategy for PD... - Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?Yaping Chu
Department of Neurological Sciences, Rush University Medical Center, 1735 West Harrison Street, Chicago, IL 60612, USA
Neurobiol Dis 25:134-49. 2007..We further hypothesize that preventing the age-related accumulation of non-aggregated alpha-synuclein might be a simple and potent therapeutic target for patients with PD... - Proteasome inhibition and Parkinson's disease modelingJordi Bove
Department of Neurology, Columbia University, New York, NY, USA
Ann Neurol 60:260-4. 2006..Although theoretically appealing, this specific model of Parkinson's disease appears to exhibit poor reproducibility... - Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeysDwaine F Emerich
LCT BioPharma, Providence, RI 02906, USA
Neurobiol Dis 23:471-80. 2006..43% in controls) and striatum volume (10% decrease vs. 40% in controls). These data indicate that CP transplants might be useful for preventing the degeneration of neurons in HD... - Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's diseaseJodi L McBride
Department of Neurological Sciences, Rush University Medical Center, 1735 West Harrison Street, Suite 300, Chicago, IL 60612, USA
Proc Natl Acad Sci U S A 103:9345-50. 2006..These data further support the concept that viral vector delivery of GDNF may be a viable treatment for patients suffering from HD... - Neural repair strategies for Parkinson's disease: insights from primate modelsKatherine Soderstrom
Department of Neurological Science, Research Center for Brain Repair, Rush University Medical Center, Chicago, IL 60612, USA
Cell Transplant 15:251-65. 2006..Finally, the contribution of primate PD models to our understanding of the etiology and pathology of human PD is discussed... - Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's diseaseBiplob Dass
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60657, USA
Neurology 66:S89-103. 2006..Long term safety and efficacy trials have not been performed in PD patients and the potential of unanticipated side effects must be addressed. Further, neither treatment is expected to improve the non-dopaminergic features of PD... - Age-related alterations in GABA(A) receptor subunits in the nonhuman primate hippocampusRobert A Rissman
Department of Neurobiology and Anatomy, Graduate Program in Neuroscience, MCP Hahnemann University School of Medicine, Philadelphia, PA 19102 1192, USA
Brain Res 1073:120-30. 2006.... - Substantia nigra tangles are related to gait impairment in older personsJulie A Schneider
Rush Alzheimer s Disease Center, Rush University Medical Center, 600 S Paulina Street, Chicago, IL, USA
Ann Neurol 59:166-73. 2006..Our objective was to test the hypothesis that substantia nigra neurofibrillary tangles (NFTs) are related to parkinsonian signs in older persons with and without dementia... - Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeysJeffrey H Kordower
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
Ann Neurol 60:706-15. 2006..INTERPRETATION: These data demonstrate that AAV2-NTN (CERE-120) can preserve function and anatomy in degenerating nigrostriatal neurons and are supportive of ongoing clinical tests in Parkinson's disease patients... - Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonismTimothy J Collier
Department of Neurology, University of Cincinnati, PO Box 670525, 265 Albert Sabin Way, Cincinnati, OH 45267, USA
Neurobiol Dis 26:56-65. 2007.... - Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's diseaseShilpa Ramaswamy
Department of Neuroscience, Rush University Medical Center, 1735 West Harrison Street, Suite 300, Chicago, IL 60612, USA
Neurobiol Dis 26:375-84. 2007..Stereological counts revealed a significant protection of NeuN-ir striatal neurons from 3NP toxicity by AAV2-NTN. These data support the concept that AAV2-NTN might be a valuable treatment for patients with Huntington's disease... - Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's diseaseDeanna M Marchionini
Dept Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Brain Res 1147:77-88. 2007..Thus, PTN was identified as a factor that plays a role in the nigrostriatal system during development and in response to disease, and may therefore be useful for neuroprotection or reconstruction of the DA system... - Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's diseaseAnamitra Ghosh
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Proc Natl Acad Sci U S A 104:18754-9. 2007..These findings were specific because mutated NBD peptide had no effect. We conclude that selective inhibition of NF-kappaB activation by NBD peptide may be of therapeutic benefit for PD patients... - Deep brain stimulation for treatment of obesity in ratsSepehr Sani
Department of Neurosurgery, Rush University Medical Center, Chicago, Illinois 60612, USA
J Neurosurg 107:809-13. 2007.... - Age-related decreases in Nurr1 immunoreactivity in the human substantia nigraYaping Chu
Department of Neurological Sciences, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
J Comp Neurol 450:203-14. 2002..These data demonstrate that age-related decline of DA phenotypic markers is associated with down-regulation of Nurr1 expression in the SN... - Animal models of Huntington's diseaseShilpa Ramaswamy
Department of Neuroscience, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL 60612, USA
ILAR J 48:356-73. 2007..This article examines the aforementioned models and describes their use in HD research, including aspects of the creation, delivery, pathology, and tested therapies for each model... - Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patientKatie Kompoliti
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 22:1630-3. 2007..There were few surviving cells staining with chromogranin A. The absence of TH-staining cells in the transplant 16 years after surgery provides further evidence that adrenal medullary transplants do not survive in the long term... - AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's diseaseMehdi Gasmi
Ceregene Inc, San Diego, CA 92121, USA
Neurobiol Dis 27:67-76. 2007..These results support the ongoing CERE-120 clinical program in PD patients... - Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeysChristopher D Herzog
Ceregene Inc, San Diego, CA 92121, USA
Mov Disord 22:1124-32. 2007.... - Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerabilityNicholas M Kanaan
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
J Comp Neurol 502:683-700. 2007..Furthermore, the results begin to characterize the nature of the link between aging and PD, and they support the concept that aged monkeys represent a valuable model for studying specific events preceding PD... - Nurr1 in Parkinson's disease and related disordersYaping Chu
Department of Neurological Science, Rush University Medical Center, Chicago, Illinois 60612, USA
J Comp Neurol 494:495-514. 2006..These data demonstrate that Nurr1 deficiency in dopaminergic neurons is associated with the intracellular pathology in both synucleinopathies and tauopathies... - Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian ratsEleonora Maries
Department of Neuroscience, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, N. Chicago, IL 60064, USA
Neurobiol Dis 21:165-80. 2006..The onset of forelimb-facial stereotypy correlated with measures of increased graft function... - RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeysBiplob Dass
Department of Neurological Sciences, Rush University Medical Center, 1735 W. Harrison Street, Chicago, IL 60657, USA
Neurobiol Aging 27:857-61. 2006.... - Knockout of p75NTR does not alter the viability of striatal neurons following a metabolic or excitotoxic injuryRose Hanbury
Research Center for Brain Repair and Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, IL 60612, USA
J Mol Neurosci 20:93-102. 2003..The results indicate that the expression of p75NTR within reactive astrocytes in the mouse striatum is not a key factor in protecting neuronal cell death following metabolic and excitotoxic insults... - Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNFJodi L McBride
Department of Neurological Sciences, Rush Presbyterian, St Luke s Medical Center, Chicago, IL 60612, USA
Exp Neurol 181:213-23. 2003..These data indicate that the viral-mediated gene transfer of GDNF into the striatum provides neuroanatomical and behavioral protection in a rodent model of HD... - GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insultsRose Hanbury
Research Center for Brain Repair and Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, Illinois 60612, USA
J Comp Neurol 461:307-16. 2003..These data strongly suggest that the expression of GFAP is implicated with the production of GDNF to a degree that confers neuroprotection after an excitotoxic or metabolic insult... - Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegenerationHeather C Salzberg-Brenhouse
Division of Biological Research, Alkermes, Inc, 88 Sidney St, Cambridge, MA 02139, USA
J Pharmacol Exp Ther 306:218-28. 2003.... - Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNFJodi L McBride
Department of Neurological Sciences, Research Center for Brain Repair, Rush University, 2242 W. Harrison Street, Chicago, IL 60612, USA
Prog Brain Res 138:421-32. 2002 - Etiology of Parkinson's disease: Genetics and environment revisitedKathy Steece-Collier
Department of Neurological Sciences, Rush Presbyterian Medical Center, Chicago, IL 60612, USA
Proc Natl Acad Sci U S A 99:13972-4. 2002 - Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degenerationStephane Palfi
Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
J Neurosci 22:4942-54. 2002..Thus, GDNF may mediate plasticity in the dopamine-depleted primate brain, which may serve to compensate for cell loss by converting striatal neurons to a dopaminergic phenotype... - Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitorsRose Hanbury
Research Center for Brain Repair and Department of Neurological Sciences, Rush Presbyterian Medical Center, 2242 West Harrison Street, Chicago, IL 60612, USA
J Comp Neurol 444:291-305. 2002..The expression of the p75(NTR) receptor after these chemical lesions support the concept that this receptor plays a role in the initiation of endogenous cellular events associated with CNS injury... - Behavioral and morphological comparison of two nonhuman primate models of Huntington's diseaseBen Zion Roitberg
Department of Neurosurgery, University of Illinois, 912 S Wood Street, M C 799, Chicago, IL 60612, USA
Neurosurgery 50:137-45; discussion 145-6. 2002..No effective treatment exists, and thus stable primate models could aid in the development of novel therapies... - Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairmentSteven T DeKosky
Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Ann Neurol 51:145-55. 2002..The upregulation in frontal cortex and hippocampal ChAT activity could be an important factor in preventing the transition of MCI subjects to AD... - Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's diseaseElliott J Mufson
Department of Neurological Sciences, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
J Comp Neurol 443:136-53. 2002..Although there was no difference in p75(NTR) CBF cell reduction between MCI and AD, it remains to be determined whether these findings lend support to the hypothesis that MCI is a prodromal stage of AD... - A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's diseaseC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
Ann Neurol 54:403-14. 2003..Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on these results... - Human neural stem cell transplants improve motor function in a rat model of Huntington's diseaseJodi L McBride
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
J Comp Neurol 475:211-9. 2004..Taken together, these data demonstrate that striatal transplants of human fetal stem cells elicit behavioral and anatomical recovery in a rodent model of Huntington's disease... - Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeysKatie Kompoliti
Department of Neurological Sciences, Rush University Medical Center, Rush University, Chicago, Illinois 60612, USA
J Comp Neurol 472:193-207. 2004.... - Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonismTimothy J Collier
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Exp Neurol 191:S60-7. 2005..Third, the aging-related chronic increase in combined striatal trophic activity was not attributable to BDNF or GDNF as these molecules either decreased or did not change with aging... - A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer diseaseMark H Tuszynski
Department of Neurosciences, University of California at San Diego, La Jolla 92093, USA
Nat Med 11:551-5. 2005..05) increases in cortical 18-fluorodeoxyglucose after treatment. Brain autopsy from one subject suggested robust growth responses to NGF. Additional clinical trials of NGF for Alzheimer disease are warranted... - Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeysYong Tang
Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology, Mount Sinai School of Medicine, New York, NY 10029, USA
Cereb Cortex 14:215-23. 2004.... - Primate models of Parkinson's diseaseTimothy J Collier
Department of Neurological Sciences, Research Center for Brain Repair, Rush Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA
Exp Neurol 183:258-62. 2003 - RNA amplification of bromodeoxyuridine labeled newborn neurons in the monkey hippocampusScott E Counts
Department of Neurological Sciences, Alla and Solomon Jesmer Chair in Aging, Rush University Medical Center, 1735 W. Harrison Street, Suite 300, Chicago, IL, USA
J Neurosci Methods 144:197-201. 2005..The present study demonstrates for the first time that BrdU immunohistochemisty is compatable with gene array technology in the primate hippocampus to evaluate subclasses of genes in newborn neurons... - Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeysJiandong Hao
Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology, Mount Sinai School of Medicine, New York, New York 10029, USA
J Comp Neurol 465:540-50. 2003.... - Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile ratsJames B Koprich
Department of Neurological Sciences, Rush University, Rush-Presbyterian-St. Luke's Medical Center, 2242 West Harrison Street, Suite 265, Chicago, IL 60612, USA
Neurotoxicol Teratol 25:509-17. 2003..Further investigation is warranted to elucidate possible mechanisms of action and to monitor children gestationally exposed to MDMA... - Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elementsNicholas A DiProspero
Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Neurocytol 33:517-33. 2004..We propose that mutant huntingtin affects proteins involved in synaptic function and cytoskeletal integrity before symptoms develop which may influence early disease onset and/or progression... - The role of alpha-synuclein in Parkinson's disease: insights from animal modelsEleonora Maries
Department of Neuroscience, The Chicago Medical School, 3333 Green Bay Road, N. Chicago, Illinois 60064, USA
Nat Rev Neurosci 4:727-38. 2003 - The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeysJamie L Eberling
Department of Neurology and Center for Neuroscience, University of California, Davis, 95616, USA
Exp Neurol 178:236-42. 2002..These findings show that GPI-1046 does not have regenerative effects in MPTP-treated primates and suggest that there may be species differences with respect to the trophic effects of GPI-1046 on nigrostriatal DA neurons... - Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical studyBen Roitberg
Department of Neurosurgery M C 799, University of Illinois at Chicago, 912 S Wood St, Chicago, IL 60612, USA
Neurol Res 25:68-78. 2003..Our model may be particularly suitable for studies testing the effects of therapeutic strategies involving neural or stem cell transplantation, trophic factors or gene therapy... - Huntington's disease: pathological mechanisms and therapeutic strategiesShilpa Ramaswamy
Department of Neuroscience, Rush University Medical Center, Chicago, IL 60612, USA
Cell Transplant 16:301-12. 2007..This review describes the disease pathology in HD and addresses many of the past and emerging therapeutic strategies... - Survival and early differentiation of human neural stem cells transplanted in a nonhuman primate model of strokeBen Z Roitberg
Department of Neurosurgery, University of Illinois, Chicago, Illinois 60612, USA
J Neurosurg 105:96-102. 2006..Neural cell transplantation has been proposed as a treatment after stroke. The purpose of this study was to establish if human neural stem cells (HNSCs) could survive in the nonhuman primate brain after an ischemic event... - Distribution of high affinity choline transporter immunoreactivity in the primate central nervous systemLaura Kus
Department of Neurological Sciences, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612
J Comp Neurol 463:341-57. 2003..The present observations indicate that the present CHT antibody labels cholinergic structures within the primate CNS and provides an additional marker for the investigation of cholinergic neuronal function in aging and disease...
Research Grants
- DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYSJeffrey Kordower; Fiscal Year: 2006..This application will determine whether potent dopaminergic gene therapies influence dyskinesias in the best animal model of PD. ..
- TH and GTPCHI gene therapy for Parkinson's diseaseJeffrey Kordower; Fiscal Year: 2007..These studies will determine the safety and efficacy of gene delivery of LDOPA and determine whether this approach is appropriate for clinical trials. ..
- TH and GTPCHI gene therapy for Parkinson's diseaseJeffrey H Kordower; Fiscal Year: 2010..These studies will determine the safety and efficacy of gene delivery of LDOPA and determine whether this approach is appropriate for clinical trials. ..